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TABLE 1 Patient Characteristics and Follow-Up (n ¼ 19)
Age, yrs 73.6  7.4
Male 13 (68.4)
Mean CHADS2 score 3.1  1.1
Mean CHA2DS2-VASc score 4.5  1.4
Mean HAS-BLED score 4.1  1.3
Post-Lariat anticoagulation* 1 (5.3)
Post-Lariat antiplatelet agents 4 (21.1)
Median time to clot detection, days 46 (17–428)
Location of clot
Endocardial surface of the ligated site 17 (89.5)
Coumadin ridge 1 (5.3)
Within the LAA through the leak into the LA 1 (5.3)
Average clot size, mm 11  10
Anticoagulation started 19 (100)
Warfarin 7 (36.9)
Novel oral anticoagulants† 12 (63.2)
Clot resolution‡ 16 (84.2)
Mean time to clot resolution, days 91 (34–228)
Clinical stroke or thromboembolism 0 (0)
Major bleeding during follow-up 0 (0)
Minor bleeding during follow-up 1 (5.5)
Values are mean  SD, n (%), or median (range). *One patient was on oral anti-
coagulation but was noncompliant. †One patient was on antiplatelet agents but
was switched to novel oral anticoagulants. ‡Three patients are still in follow-up.
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, dia-
betes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74
years, sex category; CHADS2 score ¼ congestive heart failure, hypertension, age
$75 years, diabetes mellitus, stroke/transient ischemic attack; HAS-BLED ¼ hy-
pertension, abnormal renal/liver function, stroke, bleeding history or predisposi-
tion, labile international normalized ratio, elderly (>65 years), drugs/alcohol
concomitantly; LA ¼ left atrium; LAA ¼ left atrial appendage.
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1596receive antiplatelet or anticoagulant therapy during
this period.
The risk of LA thrombus in the absence of anti-
coagulation use post-procedure is low and is more
frequently seen during the ﬁrst 3 months after LAA
ligation. Periodic imaging studies are essential for
early detection of an LA thrombus. With prompt
initiation of anticoagulation and close supervision, an
LA thrombus can be managed safely.*Dhanunjaya Lakkireddy, MD
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Ischemic Heart Disease
Meet the Needs of Those
With Ischemia?Since 1990, multiple randomized clinical trials (RCTs)
and subsequent meta-analyses have compared the
outcome of percutaneous coronary intervention (PCI)
medical therapy for stable ischemic heart disease with
no difference in primary outcome (death and/or
myocardial infarction [MI]) between the 2 approaches.
The reasons for this are not clear. It is certainly possible
that there is no difference between the 2 strategies;
alternatively, the patient populations may not have
been appropriate, or the study hypothesis may not
have been sufﬁciently focused on the right question.
From 1980 until now, approximately 195,213 pa-
tients have been screened for enrollment in trials, of
FIGURE 1 Percentage of Patients With Coronary
Atherosclerosis Included, Without Ischemia or Angina
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Statistically signiﬁcant (p < 0.0001) and wide variation between
studies; <10% for RITA to nearly 80% for MASS2. ACIP ¼
Asymptomatic Cardiac Ischemia Pilot; ACME ¼ Angioplasty
Compared to Medicine; AVERT ¼ Atorvastatin Versus Revascu-
larization Treatment; COURAGE ¼ Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation; FAME 2 ¼
Fractional Flow Reserve Versus Angiography for Multivessel
Evaluation 2; MASS ¼ Medicine, Angioplasty or Surgery Study;
RITA ¼ Randomized Intervention Treatment of Angina Trial.
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1597whom only 3.2% were randomized and about 26% did
not have a positive noninvasive test for ischemia or
symptoms of angina. Moreover, the percentage of
patients with coronary atherosclerosis included in the
trials, without proven ischemia or angina, is quite
variable among the studies (Figure 1).
It can be difﬁcult to interpret the results of the
clinical trials because of missing data in the published
papers and because the differing knowledge about
ischemia at the time of each trial. At the time of the
earlier RCTs, the common thought was that the simple
presence of stable stenosis, even in the absence of
a positive provocative test, was associated with an
adverse cardiovascular event, and for this reason, PCI
should be able to improve the natural history. It was
consistent with the original hypothesis to include pa-
tients with angiographic coronary artery disease (CAD),
even in the absence of inducible ischemia. Only
recently—in the era of the COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive Drug
Evaluation) trial (1) and the FAME (Fractional Flow
Reserve Versus Angiography for Multivessel Evalua-
tion) trial (2)—that the fundamental prognostic sig-
niﬁcance of inducible ischemia has been more
appreciated, and even then not entirely consistently.
Thus, the COURAGE trial conclusively demonstrated
that PCI as an initial therapeutic strategy does notreduce the risk of death, MI, or other major car-
diovascular events when added to optimal medical
therapy (OMT) in patients with stable ischemic
heart disease. However, even the COURAGE trial
cannot be generalized to patients with a large ischemic
burden (1).
In 2009, the FAME investigators reported that PCI
guided by fractional ﬂow reserve (FFR) could reduce
the incidence of cardiovascular events when com-
pared with angiographically guided PCI. The primary
endpoint (composite of major cardiac events) at 1
year occurred in signiﬁcantly fewer patients in the
FFR-guided group than in the angiographic-guidance
group (13.2% vs. 18.3%; p ¼ 0.02) (2,3). Recently, on
the basis of the FAME I trial, De Bruyne et al. (4)
hypothesized that in patients with stable CAD and
stenosis, PCI performed on the basis of the FFR
would be superior to OMT. The 2-year follow-up
of the FAME 2 trial reported that the beneﬁt of
FFR-guided PCI was a decrease in urgent revascu-
larization at the expense of 351 more re-
vascularizations in the PCI group when compared
with the OMT group, without an effect on death or
MI. Still, 10% of patients in the PCI group had angina
at 6-month follow-up despite optimal revasculariza-
tion, with 80% in the OMT group free from angina.
Patients included in the registry group of the FAME 2
trial had the same clinical presentation despite
absence of the signiﬁcant stenosis (4).
RCTs remain the most accepted design for esti-
mating the effects of interventions, but they have
not consistently answered the question of primary
interest: are these results generalizable to patients
with ischemic heart disease? The answer is equivocal
because clinical trials have not consistently repre-
sented patients with ischemia that could potentially
beneﬁt from PCI. RCTs comparing OMT to PCI are
associated with 2 main problems: low generalizability
(trials with strict selection criteria) or suboptimal in-
ternal validity (e.g., proven CAD without proven
ischemia). Trials comparing OMT to PCI do not uni-
formly and consistently reﬂect the ischemic popula-
tion. Moreover, the complexity of the mechanisms
contributing to myocardial ischemia is largely under-
estimated, and thousands of revascularization pro-
cedures are performed every year (5). Clinical
trials are the most powerful method to avoid bias,
and selection of the right population that could
beneﬁt from revascularization is mandatory.*Doralisa Morrone, MD
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Litigation
A Fellow’s PerspectiveDr. Badri makes some cogent points in his recent
opinion piece, “Medical Malpractice Litigation: A
Fellow’s Perspective” (1). We, too, are concerned with
trainees’ lack of knowledge of medical professional
liability (MPL) issues. We also agree with Hochberg
et al. (2) that this is a topic that should be part of the
professionalism education for all residents and
fellows-in-training (FITs), and we suggest that having
an understanding of MPL is part of achieving
competence in systems-based practice as well.
MPL may not be a topic of signiﬁcant attention
in most cardiology fellowship programs, but it is
recognized as a small, but real, part of the cardiology
curriculum. The American Board of Internal Medi-
cine (ABIM) lists professional liability as a topic for
a proportion (<2%) of questions on its cardiovascu-
lar disease (3) and interventional cardiology certiﬁ-
cation examinations (4). Interestingly, MPL is not
currently treated in the blueprints of the cer-
tifying examinations in advanced heart failure
and transplant cardiology or in clinical cardiac
electrophysiology.In an effort to ﬁll this gap in training for FITs, the
American College of Cardiology (ACC) has created an
opportunity for all interested FITs to learn the basics
of MPL. In a voluntary educational research project,
FITs may agree to participate in the testing of
an online self-assessment program that has been
approved by the Institutional Review Board of Med-
Star Health Research Institute in Washington, DC.
The “Fellows-in-Training Patient Safety and Risk
Management Study” may be accessed online as a
self-paced program that is designed to take approxi-
mately 10 to 12 h to complete (5). Approximately 30
FITs have volunteered for the project to date. FITs
who are interested in learning more may contact the
authors.
Non-FIT members of the ACC may access the same
MPL curriculum with the Patient Safety and Risk
Management Self-Assessment Program, which pro-
vides up to 12 h of continuing medical education
and continuing education credit and 10 points of
ABIM medical knowledge maintenance of certiﬁca-
tion credit.
Finally, we would quibble a bit over the term
medical malpractice employed by Dr. Badri. The term
preferred by the Physician Insurers Association of
America and the National Association of Insurance
Commissioners is medical professional liability. This
is because the term medical malpractice is, in itself,
prejudicial and potentially deleterious to physicians
who ﬁnd themselves involved in a legal action. The
phrase MPL has the beneﬁcial characteristic of preci-
sion without the negative connotation of negligence
on the part of the physician. Culpability should not be
the presumption in these cases because no fault is
found or payment made in 82% of MPL claims
brought against cardiologists.Daisy F. Lazarous, MD
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